Nurix Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Nurix Therapeutics (Nasdaq: NRIX), a clinical stage biopharmaceutical company focusing on targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2024:
1. 2024 Wells Fargo Healthcare Conference in Boston, MA (September 5)
2. H.C. Wainwright 26th Annual Global Investment Conference in New York City (September 9)
3. Baird 2024 Global Healthcare Conference in New York City (September 10)
Key executives, including CEO Arthur T. Sands, CFO Hans van Houte, and CBO Jason Kantor, will participate in fireside chats and presentations. Most events will be webcast live and accessible through the Investors section of Nurix's website, with recordings available for 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction – NRIX
On the day this news was published, NRIX declined 0.36%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in September:
- 2024 Wells Fargo Healthcare Conference (Boston, MA)
Fireside chat: Thursday, September 5, 2024, from 4:30 – 5:05 p.m. ET - H.C. Wainwright 26th Annual Global Investment Conference (New York City)
Fireside chat: Monday, September 9, 2024, from 9:30 – 10:00 a.m. ET - Baird 2024 Global Healthcare conf (New York City) (will not be webcast)
Presentation: Tuesday, September 10, 2024, from 9:50 – 10:20 a.m. ET
Unless otherwise specified, fireside chats will be webcast live and may be accessed via links in the Investors section of the Nurix website under Events and Presentations. The archived webcasts will be available on the Nurix website for 30 days after the event.
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What investor conferences will Nurix Therapeutics (NRIX) attend in September 2024?
Who will represent Nurix Therapeutics (NRIX) at the upcoming investor conferences?
Will Nurix Therapeutics' (NRIX) conference presentations be available for viewing online?
What is the focus of Nurix Therapeutics' (NRIX) drug development?
